Match Document Document Title
DE202018005641U1 Dietary supplement for the prevention or treatment of sleep disorders  
Dietary supplement in the form of a water-soluble powder and / or granules for the preparation of a ready-to-drink preparation containing (a) L-tryptophan and / or melatonin; (b) passionflower...
DE202017006840U1 Dietary supplement comprising a galactose-containing multivitamin-mineral complex  
Nutritional supplement comprising galactose and at least one vitamin from the group of B vitamins and di- and / or trivalent minerals.
DE202018101559U1 A kind of secondary plant substance  
A type of secondary plant matter which comprises the chemical compounds based on formula (1), formula (2), formula (3), formula (4) and formula (5), or mixtures thereof:wherein the phytochemicals...
DE19861497B3 Babies' food and their use for the promotion of human colorectal flora  
According to the invention, baby food containing at least two different, soluble carbohydrates is provided. This baby food is characterized by the fact that the carbohydrates consist of a...
DE19861508A1 Kohlenhydratmischung  
Erfindungsgemäß wird eine Kohlenhydratmischung für diätetische Nahrungen und Pharmazeutika enthaltend mindestens zwei unterschiedliche, lösliche Kohlenhydrate zur Verfügung gestellt. Diese...
DE102014013885A1 dialysis solution  
The present invention relates to a dialysis solution containing bicarbonate, calcium and phosphate, where the phosphate dialysis solution having a concentration in the range of up to 0.4 mmol / l,...
DE10066235C5 Method and medicament for the inhibition of expression of a given gene  
A method for inhibiting the expression of a given target gene in a mammalian cell, wherein a vector for coding at least one consisting of 15 to 2 base pairs oligoribonucleotide with...
DE69314239C5 Process for Stereoselektivglycosylierung  
A process for the synthesis of a β-anomer enriched nucleoside of the formula which, if appropriate in a suitable solvent, performing a nucleophilic SN2-substituting a sulfonyloxy group (Y) of an...
DE102009015608A1 Use of alkyl glycosides or Alkylglycosidmischungen as active ingredients for the inhibition of microbial growth, and compositions which contain said alkylglycosides  
The present invention relates to the use of an alkyl glycoside or a mixture of at least two alkyl glycosides as the active ingredient for the inhibition of microbial growth, particularly in a...
DE102007052119A1 New coumermycin A1-derivative, useful as biologically active substance and as antibiotics or cytostatics, and for preventing diseases caused by bacteria or tumor  
Coumermycin A1-derivative (I), is new. Coumermycin A1-derivative of formula (I), is new. R1, R2 : CH 3, halo or H, preferably H, F, Cl, Br or I, where both R1, R2 are not simultaneously CH 3. An...
DE10085149B4 A process for preparing acarbose with high purity  
process for producing highly pure acarbose with an acarbose content of at least 98%, comprising the steps of: Filtering a acarbose containing fermentation culture, Adjusting the pH of the Filtrate...
DE102006053385B4 Enterococcus faecalis antigen  
Enterococcus faecalis strain type 5 antigen, at least one disaccharide unit comprising, having the following formula: where R1 OH, X = O, Y = O and CA lactyl is.
DE102006053385A1 Enterococcus faecalis and / or Enterococcus faecium antigen  
The This invention relates generally to the field of detection and prevention of infectious diseases caused by Enterococcus faecalis and / or Enterococcus faecium caused. In particular relates to...
DE10066235B4 Targeted inhibition of gene expression by administration of double stranded oligoribonucleotide to a cell, useful for treating humans, animals and plants against viral infection  
A new method to inhibit the expression of a predetermined target gene in a cell, comprises introducing an oligoribonucleotide with double stranded structure (dsRNA) or a vector coding for the...
DE10080167B4 Medicament for inhibiting the expression of a given gene  
drug with at least one 15 and 49 base pairs containing oligoribonucleotide with double Structure (dsRNA) for inhibiting the expression of a given target gene in mammalian cells, wherein the...
DE202007000338U1 Composition, useful to prevent and/or to treat vascular occlusive diseases, e.g. arteriosclerosis diseases and coronary heart disease, comprises ethanol, water, a non-toxic acid and/or a sugar  
Composition (I) for the prevention and/or treatment of vascular occlusive diseases, obtained by mixing ethanol, water, a non-toxic acid and/or a sugar, is new. ACTIVITY : Antiarteriosclerotic;...
DE102005029126A1 New cripowellin derivatives useful in the preparation of medicament for the treatment of cancer or other proliferative diseases  
Cripowellin derivatives (I) and (II) are new. Cripowellin derivatives of formulae (I) and (II) are new. R : H or -OR 1>; R-a : H or OH; either R 1>H, 2-tetrahydropyranyl, optionally substituted...
DE4323567B4 Aucubin for treating a hepatitis B virus infection  
use of Aucubin, the aglycone of Aucubin or a pharmaceutically acceptable salt or the aglycone of aucubin of aucubin for treating a hepatitis B virus infection.
DE19781703B4 Effective against tumors Anthracyclindisaccharide, fermentation processes for their preparation and therapeutic composition containing them  
connection of the formula: wherein R represents a -COCH3-, -CHOHCH3- or -COCH2OH group, and their pharmaceutically acceptable addition salts.
DE102005023636A1 Drug combinations of glucosyl glycerides and creatine and / or creatinine  
drug combinations out(I) one or more glucosyl glycerides,(Ii) creatine and / or creatinine and / or one or more creatine derivatives, chosen from the group of creatine phosphate, creatine sulfate,...
DE102005018642B4 Use of compounds to inhibit the glyoxalases  
Using a combination of a. at least one and Glykolysesubstrat b. at least one compound of the general formula (I),wherein R1 is a branched or unbranched alkyl, alkenyl, alkynyl or cycloalkyl...
DE60115222T2 COMBINING defibrotide AND G-CSF AND THEIR USE FOR ACTIVATION hematopoietic Progenitor Cells  
A description is given of a method of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the method is characterised by the administration...
DE102004061145A1 New glucopyranosyl-substituted benzene derivatives are sodium-dependent glucose cotransporter inhibitors, useful for treating e.g. metabolic disorders (type 1 and type 2 diabetes mellitus or metabolic acidosis)  
Glucopyranosyl-substituted benzene derivatives (I) and their tautomers, sterioisomers andsalts are new. Glucopyranosyl-substituted benzene derivatives of formula (I) and their tautomers,...
DE102004054603A1 New D-xylopyranosyl-substituted phenyl compounds are sodium-dependent glucose cotransporter inhibitors useful to prevent or treat e.g. diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis  
D-Xylopyranosyl-substituted phenyl compounds (I) and tautomers and/or stereoisomers and salts are new. D-Xylopyranosyl-substituted phenyl compound of formula (I) and tautomers and/or stereoisomers...
DE102004048388A1 D-pyranosyl substituted phenyls, medicaments containing these compounds, their use and processes for their preparation  
D-pyranosyl substituted Phenyls of general formula I, wherein the radicals R1 to R5, X, Z and R7a, R7b, R7c are as defined in claim 1, having an inhibitory effect on the sodium-dependent glucose...
DE102004046583A1 New D-xylopyranosyl-phenyl-substituted cycle compounds useful for treating e.g. diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis  
D-xylopyranosyl-phenyl-substituted cycle compounds, their tautomers, stereoisomers, mixtures and salts are new. D-xylopyranosyl-phenyl-substituted cycle compounds of formula (I), their tautomers,...
DE102004046012A1 New D-glucopyranosylphenyl-substituted cyclic compounds useful as sodium-dependent glucose cotransporter inhibitors for treating metabolic diseases, e.g. diabetes  
D-glucopyranosylphenyl-substituted cyclic compounds (I) are new. D-glucopyranosylphenyl-substituted cyclic compounds of formula (I) and their tautomers, stereoisomers and salts, other than...
DE102004040006A1 A pharmaceutical composition comprising galactose, selenium, vitamin E and / or phosphatidylcholine and pharmaceutical use of galactose  
The This invention relates to a pharmaceutical composition comprising galactose and / or at least one and Galaktosederivat at least one additive selected of at least one added selenium and vitamin...
DE102004039096A1 New D-xylopyranosyl-phenyl-substituted cycle compounds useful for treating e.g. diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis  
D-xylopyranosyl-phenyl-substituted cycle compounds, their tautomers, stereoisomers, mixtures and salts are new. D-xylopyranosyl-phenyl-substituted cycle compounds of formula (I), their tautomers,...
DE102004032823A1 New D-xylopyranosyl-substituted phenyl compounds are sodium-dependent glucose cotransporter inhibitors useful to prevent or treat e.g. diabetes mellitus, complications of diabetes, metabolic acidosis or ketosis  
D-Xylopyranosyl-substituted phenyl compounds (I) and tautomers and/or stereoisomers and salts are new. D-Xylopyranosyl-substituted phenyl compound of formula (I) and tautomers and/or stereoisomers...
DE10258007B4 Aromatic Fluorglycosidderivate, medicaments containing these compounds and methods for making these medicines  
compounds of formula I, which mean R1, R2 OH, F or H; R3 OH or F, where one of R1, R2, R3 F must be; AO, NH, CH2, S or a Binding; R4, R5, R6 hydrogen, F, Cl, Br, I, OH, CF3, NO2, CN, COOH, CO...
DE102004031588A1 Using Äpfelsäureglucosiden as flavorings  
described the use of a Äpfelsäureglucosids [2- (glucosyl) -butan-1,4-dioic acid] or a physiologically salt of a akzeptalen Äpfelsäureglucosids as a flavoring, particularly as umami flavor and...
DE10258008B4 Heterocyclic Fluorglycosidderivate, medicaments containing these compounds and methods for making these medicines  
compounds of formula I, which mean R1, R2 OH, F or H; R3 OH or F, where one of R1, R2, R3 F must be; AO, NH, CH2, S or a Binding; X is O, S or optionally substituted with R6 N, in the case X = O...
DE102004034690A1 Methylidene-D-xylopyranosyl and oxo-D-xylopyranosyl-substituted phenyls, medicaments containing these compounds, their use and processes for their preparation  
D-xylopyranosyl-substituted phenyls of the general formula I, wherein the radicals R1 to R5, X, Z and R7a, R7b, R7c are as defined in claim 1, having an inhibitory effect on the sodium-dependent...
DE202005016250U1 Topiramate and pharmaceutical formulations thereof  
topiramate characterized in that it is present in highly pure form and at least 90% of the particles have a particle size of ≤ 250 microns.
DE19603788B4 Active extract of devil's claw root, these containing human or veterinary medicinal preparation, method for producing a highly concentrated extract of Radix Harpagophyti or Herba and Radix Scrophularia and also its use  
drug extract of devil's claw root, available by a method in which a crude aqueous extract of Radix Harpagophyti is brought into contact with a non-ionic adsorbent resin and active substances...
DE10112926B4 Using aminooxyacetate for tumor treatment  
use of aminooxyacetate for the treatment of tumors.
DE102004017996A1 Stable anionic liposome depot system for prolonged release of protein or peptide drugs, e.g. insulin, comprising phosphatidyl choline, cholesterol, anionic lipid(s) and cationic polymer  
The use of a depot system (I) containing anionic liposomes is claimed for retarded drug release, where (I) comprises protein and/or peptide active agent(s), saturated synthetic phosphatidyl...
DE19829844B4 Use of D-galactose to prevent necrosis  
use of D-galactose and / or one or more D-galactose derivative / s - except hepatotoxic acting derivatives with galactosamine - prevention or reduction of necrosis or cell tissue damage.
DE4126475B4 13-dihydro-3 '- (2-alkoxy-4-morpholinyl) anthracycline, processes for their preparation, their use and compositions containing  
Anthracycline glycoside of the general formula (A) or a pharmaceutically acceptable salt thereof where R1 H, OH or OCH3 is; one of the groups R2 and R3 is OH and the other is H; R4 is H or OH; R5...
DE102004017793A1 Use of trioxacarcins for treatment and prevention of infectious diseases, also new trioxacarcins for treatment of e.g. tumors, inflammatory and autoimmune diseases  
Use of trioxacarcins (I), or their stereoisomers, tautomers and salts, for preparing a composition for treatment and prevention of infectious diseases caused by fungi, parasites, viruses and...
DE4444606B4 Process for the preparation of sennosides A and B.  
process for the preparation of sennosides A and B, in which rheinanthrone-8-glucoside with oxygen or an oxygen source to the sennosides A and B is oxidized, characterized in that the oxidation...
DE10330243A1 Use of protein derived from extremophile bacteria osmolytes for producing drugs for external treatment of eczema  
The Invention relates to the use of osmolytes, in particular ectoine and hydroxyectoin, as well as their pharmacologically acceptable Salts and / or equally acting derivatives for the preparation...
DE102004028805A1 Means to promote collagen formation  
stated is an agent for promoting the formation of collagen, characterized in that it comprises a compound of the general Formula I, in the three longitudinally dashed lines two single bonds and a...
DE10323279A1 Ready gemcitabine solutions  
The present invention relates to gemcitabine comprehensive pharmaceutical Compositions in the form of hand finished solutions for administration parenteral route. The novel solutions stand out...
DE10323278A1 Ready gemcitabine solution concentrates  
The present invention relates to gemcitabine comprehensive pharmaceutical Compositions in the form of ready-made solution concentrates for the production of solutions for administration...
DE19910682B4 Use of a combination preparation for the therapy of a fibrate-induced hyperhomocysteinemia  
Use of a combination product, the fibrates and one or more of the following active ingredients comprising: (cyano, hydroxo, methyl) cobalamin, folic acid, methyl tetrahydrofolate, leucovorin,...
DE10258007A1 New aromatic Fluorglycosidderivate, pharmaceutical compositions containing them and their use  
The invention relates to substituted aromatic Fluorglycosidderivate of the formula I, wherein the radicals have the meanings indicated, and their physiologically acceptable salts and processes for...
DE19829516B4 Water soluble native dry extract of Ginkgo biloba with a high content of flavone glycosides and terpenoids  
Water-soluble, native dry extract from plant parts of Ginkgo biloba, characterized in that it consists exclusively of ingredients of plant parts, and that it easily the European Pharmacopoeia, 3rd...
DE10300222A1 Use of active substances for the prophylaxis and / or therapy of viral diseases  
The present invention relates to the use of preferably at least one active substance for the prophylaxis and / or therapy of a viral disease, wherein said active substance at least one component...